Emanuel Peter L
ID:
|
Development of Standardized Herbal Formulation: Synergy between Momordica charantia, Aloe vera and Abelmoschus esculentus for Glycemic Control
REFNo: NS119ES
Objectives
1. To establish ethnomedical use of M. charantia and A. esculentus among indigenous community in Tanzania.
2.To establish physicochemical and stability parameters of freeze dried aqueous extracts of the three plant species separately in pre-formulation studies.
3. To evaluate efficacy of combined freeze dried extracts in different ratios of doses of M. charantia, A. esculentus and A. vera in vivo.
4. To establish safety profile of best optimal dose combination of M. charantia, A. esculentus and A. vera on healthy Wistar female rats.
5. To design a solid pharmaceutical dosage form of the optimal dose combination and evaluate its stability, safety and efficacy in vivo.
|
Tanzania |
2020-10-12 |
2023-10-12 |
Natural Sciences |
|
Degree Award |
|
Christine Aanyu
ID:
|
EQUITABLE MATERNAL CARE FOR WOMEN WITH DISABILITY (EMeralD) STUDY
REFNo: HS722ES
1) Specific Aim 1. Conduct an analysis of disability, pregnancy and birth outcomes, and maternal health care utilization data for pregnant women with disabilities in Uganda.
2) Specific Aim 2. Understand the needs and perceptions of pregnant women with disabilities and identify availability of, and barriers to accessing, maternal health care services.
3) Specific Aim 3. Formulate and develop a model for disability-friendly services for pregnant women.
|
Uganda |
2020-10-07 |
2023-10-07 |
Medical and Health Sciences |
|
Non-degree Award |
|
David Serwadda -
ID:
|
Characterizing community exposure to SARS-CoV-2 in Uganda, and assessing biological determinants of virus spread
REFNo: HS878ES
1.Assess the diagnostic sensitivity and specificity of the CoronaChekTM rapid COVID-19 IgM/IgG lateral flow test (CoronaChekTM by Hangzhou Biotest Biotech Co Ltd) for anti- SARS-CoV-2 antibodies detection in Uganda.
2.Conduct enhanced surveillance of COVID19-like symptoms in the context of an existing population cohort and assess the predictive value of prevailing symptoms for COVID-19 exposure based on rapid serological testing in this region.
3.Determine rates of sero-reactivity/positivity among key health care workers at high-volume health centers III and IV and also among PCR-negative contacts of confirmed COVID-19 cases in the region.
4.Explore ‘prior importation of COVID-19 infection in Uganda”/ pre-existing sero-reactivity (may due to ‘related’ coronavirus strains/shared epitopes) in purposively selected archived sera, prioritizing from truck drivers and commercial sex workers that was collected before the lockdown in Uganda / Rakai region.
|
Uganda |
2020-10-06 |
2023-10-06 |
Medical and Health Sciences |
|
Non-degree Award |
|
Richard Idro
ID: UNCST-2021-R013599
|
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children with Sickle Cell Anaemia in eastern and southern Africa: a double blind randomised trial (the CHEMCHA trial)
REFNo: HS709ES
Primary objective
The general objective is to determine the efficacy and safety of malaria chemoprevention with weekly single day courses of DP compared to monthly single courses of SP in children with SCA in eastern and southern Africa.
Secondary objectives
1. Assess the feasibility and stakeholder perceptions on the uptake (acceptability) and the potential for future roll-out of weekly DP vs monthly SP.
2. Determine the safety of cumulative dosing of DP, especially on cardiac function.
3. Monitor the development of malaria parasite resistance to DP in clinical isolates over time.
Assess patients’ health-related quality of life, cost-effectiveness, equity and economic implications of using weekly courses of DP vs monthly courses of SP as chemoprevention in SCA.
5. Assess acceptability of weekly courses of DP for malaria chemoprevention in SCA vs monthly courses of SP as chemoprevention in SCA.
6. Conduct policy advocacy to engage key stakeholders on policy decisions on using weekly courses of DP or monthly courses of SP for the chemoprevention of malaria in SCA.
|
Uganda |
2020-10-02 |
2023-10-02 |
Medical and Health Sciences |
|
Non-degree Award |
.jpg)
|
Richard Idro
ID: UNCST-2021-R013599
|
Hydroxyurea therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A single arm open label trial, “BRAIN SAFE II”
REFNo: HS846ES
The primary objective is to determine the impact of daily oral hydroxyurea therapy, 20- 30mg/kg/day, on the frequency and severity of Sickle Cell Vasculopathy(SCV) in a cohort of children treated for three years, as measured by 3 distinct outcomes: abnormal TCD, neurocognitive impairment and primary stroke, compared with baseline.
Secondary objectives
1.Evaluate the impact of Hydroxyurea therapy on structural SCV using MRI and MRA in a randomly selected subset of this cohort.
2.Assess changes to anemia, CRP and malnutrition status during hydroxyurea therapy, over time, compared with baseline levels.
|
Uganda |
2020-10-02 |
2023-10-02 |
Medical and Health Sciences |
|
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|